OVIDREL

This brand name is authorized in United States. It is also authorized in Australia, Brazil, Canada, Ecuador, Hong Kong SAR China, Japan, New Zealand, Singapore.

Active ingredients

The drug OVIDREL contains one active pharmaceutical ingredient (API):

1	Choriogonadotropin alpha UNII 6413W06WR3 - CHORIOGONADOTROPIN ALFA
	The principal pharmacodynamic activity in women is oocyte meiosis resumption, follicular rupture (ovulation), corpus luteum formation and production of progesterone and estradiol by the corpus luteum.
	Read more about Choriogonadotropin alpha

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
OVIDREL Solution for injection	MPI, US: SPL/Old	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
G03GA08	Choriogonadotropin alfa	G Genito urinary system and sex hormones → G03 Sex hormones and modulators of the genital system → G03G Gonadotropins and other ovulation stimulants → G03GA Gonadotropins
Discover more medicines within G03GA08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	6182J
BR	Câmara de Regulação do Mercado de Medicamentos	525413070044403
CA	Health Products and Food Branch	02262088, 02371588
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	26.642-10-05
HK	Department of Health Drug Office	52881, 62021
JP	医薬品医療機器総合機構	2413406G1020
NZ	Medicines and Medical Devices Safety Authority	11387
SG	Health Sciences Authority	13015P
US	FDA, National Drug Code	44087-1150